Agonistic Antibodies and the Role of Checkpoint Receptors in Immune Function
About this Blog
Clinical development of agonistic antibodies targeting co-inhibitor checkpoint receptors using FcγR clustering cells offers a new avenue to design therapeutics against auto-immune diseases. Eurofins DiscoverX assays can efficiently characterize agonistic antibodies for immune checkpoint activators and inhibitors. In addition, several cell lines (human and mouse) that over-express distinct types of FcγR are available to determine the best affinity with antibody therapeutic.